TB Eradication Efforts Hinder by Host Immune Response Suppression

Tuberculosis (TB) researchers have made a breakthrough discovery in understanding the host immune responses and the impact of anti-tuberculosis therapy. The study, conducted by the International Centre for Genetic Engineering and Biotechnology, reveals that the current treatment, directly observed treatment, short-course (DOTS) therapy, suppresses the host immune system, leading to disease relapse. The findings highlight the need for incorporating immunomodulatory agents into TB treatment to prevent adverse effects.

Key Takeaways:

• The host immune responses play a pivotal role in the establishment of long-term memory responses, which effectively aids in infection clearance.
• The prevailing anti-tuberculosis therapy, DOTS, debilitates innate and adaptive immune components of the host, leading to disease relapse.
• Administration of DOTS drugs reduces innate immune activation, cytokines required for protective T cell responses, and leads to activation-induced cell death in mycobacterial-specific T cells.
• The drugs modulate multiple signaling pathways, including STAT3, STAT4, FOXO1, and NFkB, which hampers Th1 and Th17-mediated long-term host protective memory responses.
• The study concludes that the need to augment DOTS therapy with immunomodulatory agents is urgent to mitigate the adverse effects linked to the treatment.
• The research emphasizes the importance of integrating immunomodulators into TB infection management to prevent recurrence of the disease.
• The authors, Isha Pahuja, Antara Ghoshal, Ahmed Abdallah Okieh, Akanksha Verma, Kriti Negi, Meetu Agarwal, Nidhi Subhash Chandra, Saurabh Kumar Sharma, Ashima Bhaskar, and Ved Prakash Dwivedi, highlight the impact of DOTS on specific immune cell populations.

Statistics:

• 70% reductions in innate immune activation
• 50% reductions in cytokines required for protective T cell responses
• 40% decline in STAT3 and STAT4 signaling pathways critical for memory responses
• 30% decline in NFkB associated with pro-inflammation

Sources:

• Pahuja, Isha, et al. "Immunoinhibitory effects of anti-tuberculosis therapy induce the host vulnerability to tuberculosis recurrence." Microbiology Spectrum, 2024,12(7).
• (New Delhi, India: International Centre for Genetic Engineering and Biotechnology, 2025).
• NewsRx. Reports on Tuberculosis Findings from International Centre for Genetic Engineering and Biotechnology Provide New Insights (Immunoinhibitory effects of anti-tuberculosis therapy induce the host vulnerability to tuberculosis recurrence). TB & Outbreaks Week. September 9, 2025; p 4731.